Lymphoma Facts

Lymphoma specifically, and cancer generally, is a moving target—our understanding of this disease is constantly evolving.

Lymphoma Facts: Incidence

So how many people will develop lymphoma? Epidemiological studies allow for estimates to be published by the National Cancer Institute, and these suggest that about 74,000 people in the United States will develop some form of lymphoma in a single year, with men being diagnosed slightly more frequently than women.

Lymphoma Facts: Mortality

While many forms of lymphoma are treatable, others do not respond well to treatment and unfortunately, lymphoma facts show approximately 21,000 people will succumb to the disease annually.

Lymphoma Facts: Survival Rates

Lymphoma is one of the more treatable and sometimes even curable cancers known to modern medicine, and this is reflected in the 5 year relative survival percentages of lymphomas almost regardless of the stage at diagnosis:

  • -- Localized disease: 81.9%
  • -- Regional disease: 76.7%
  • -- Metastatic disease: 60.2%
  • -- Stage unknown: 65.8%

A sixty percent 5 year relative survival percentage, in cancer terms, means that at least sixty percent of patients diagnosed with stage IV lymphoma can look forward to a successful treatment. This doesn't mean the treatment will be easy—not at all—but the odds are good that it will be successful.

Lymphoma Facts: Subtypes

As a cancer, lymphoma is very confusing because so much is being learned about the disease every day. Lymphomas are first divided into Hodgkin's and non-Hodgkin's categories. There are six subtypes of Hodgkin's lymphoma, but non-Hodgkin's lymphomas are far more varied and far more confusing. Currently we recognize about 40 category subtypes of non-Hodgkin's lymphomas, but in reality these categories are growing all the time, and since each subtype of lymphoma is considered to be an entirely different and independent disease than every other subtype, the lymphoma world can suddenly go from confusing to outright ridiculous.

However, what appears to be true in lymphomas may also turn out to be true across all cancers: namely, that the old anatomy-based way of designating cancer types (by organ or region) may be faulty, and that the best way to find treatment pathways and help people beat their cancer will be through determining the molecular characteristics and chromosomal translocations of the cancer cell itself, and not where it develops in the body.

Sources

  • National Cancer Institute SEER Stat Fact Sheets: Lymphoma

Related Articles

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap